Core Insights - Bempedoic acid has received strong endorsement from the AHA/ACC Multisociety Guideline for patients with statin intolerance and severe hypercholesterolemia, positioning it alongside PCSK9 mAb and ezetimibe for high-risk primary prevention and clinical ASCVD patients not at very high risk [1][2] - The guideline emphasizes the importance of early combination lipid-lowering therapy and reintroduces LDL-C goals, supporting the 'lower for longer is better' approach to cardiovascular risk reduction [1][5] Summary of Recommendations - Class 1 recommendations indicate that adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms and are at high ASCVD risk should add bempedoic acid and/or ezetimibe to lower LDL-C to <70 mg/dL and non-HDL-C <100 mg/dL [3] - For adults with clinical ASCVD experiencing statin-attributed muscle symptoms, a reduced statin dose and the addition of bempedoic acid, ezetimibe, or a PCSK9 mAb are recommended to lower LDL-C and reduce ASCVD risk [3] - In adults with diabetes who have statin-attributed side effects, initiation of ezetimibe and/or bempedoic acid or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk [3] - For adults with severe hypercholesterolemia on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb, and/or bempedoic acid is recommended to achieve LDL-C goals and reduce ASCVD risk [3] - Class 2a recommendations suggest that for adults with clinical ASCVD not at very high risk, it is reasonable to add bempedoic acid, ezetimibe, or a PCSK9 mAb to achieve LDL-C <70 mg/dL and non-HDL-C <100 mg/dL [3][7] Company Positioning - Esperion views the guideline recognition as a significant milestone that validates bempedoic acid as an evidence-based therapy for patients requiring additional LDL-C lowering or unable to tolerate statins, which strengthens its market position [2] - The endorsement is expected to accelerate the adoption and expand access to Esperion's products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) [2][10]

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Industry**: Cardiovascular therapeutics - **Recent Performance**: Reported earnings with significant growth metrics Key Financial Highlights - **Total Revenue**: $408 million, representing a **38% year-over-year growth** [2] - **TRx Growth**: **34% year-over-year** and **11% quarter-over-quarter** growth in TRx [2] Acquisition Details - **Acquisition of Corstasis**: - Focused on a newly approved nasal loop diuretic, Enbumyst, which is **40 times more potent than furosemide** [3][6] - Expected to close in the **first week of April 2026** [3] - **Transaction Value**: $75 million upfront plus up to $180 million in milestones [18] - Financing through expanding existing term loan and monetizing Japanese royalties [19] Market Opportunity - **Target Markets**: - Expanding into cardiometabolic field, addressing unmet needs in heart failure [6][7] - Anticipated to reduce hospital readmission rates, which cost between **$12,000-$18,000** per heart failure readmission [13] - **Nasal Delivery System**: - Easy to use, potentially improving patient compliance and outcomes [14][16] Commercial Strategy - **Integration Plans**: - Pre-integration phase ongoing, with plans to leverage existing commercial infrastructure for product launch [23] - Focus on payer access and relationships with specialty pharmacies [30] - **Growth Strategy for Bempedoic Acid**: - Targeting **$1 billion plus opportunities** in the U.S. market [37] - Emphasis on maximizing NEXLIZET and NEXLETOL products [39] Competitive Landscape - **Guidelines and Market Position**: - Anticipation of new guidelines to provide a tailwind for bempedoic acid [37] - Highlighting unique outcomes data to differentiate from competitors [40][41] International Markets - **Partnerships**: - Strong performance reported by Daiichi Sankyo in Europe, particularly in Germany and the UK [57][61] - Otsuka in Japan showing promising sales, with over **700 representatives** promoting the drug [61] Future Outlook - **Vision 2040**: - Focus on growing the bempedoic acid franchise, business development, and pipeline expansion [78] - Upcoming clinical trials for ESP-2001 targeting primary sclerosing cholangitis [79] - Plans to explore kidney-related therapies, complementing heart failure treatments [80] Financial Health - **Cash Position**: - Ended the year with **$168 million** in cash, with ongoing improvements to the balance sheet [72] - Commitment to deleveraging while maintaining growth [75] Conclusion - Esperion Therapeutics is positioned for significant growth through strategic acquisitions, a robust product pipeline, and a strong commercial strategy aimed at addressing unmet needs in cardiovascular care. The company anticipates continued success in 2026, building on the momentum from 2025.

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [16] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in Q4 royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [5] - The acquisition of Corstasis is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [11][14] - The company aims to grow its two franchises to multi-billion-dollar potential [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [8] - The company anticipates significant growth opportunities in the heart failure market with the launch of Enbumyst [13] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst [14] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for the launch and will provide updates on the auto-injector after the deal closes [22][25] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a cross-functional plan for the medical community [28][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and anticipates similar effects from the upcoming U.S. guidelines [39][44] Question: Triple combination products and market research - Management indicated high excitement for the triple combination therapy and clarified that it does not muddy the messaging around statin intolerance [61][62] Question: Corstasis clinical obligations and updates - There are minimal post-market obligations for Enbumyst, and management does not expect them to significantly impact operations [70] Question: Risks of concessions in 2026 - Management stated they do not foresee the need for concessions, emphasizing strong coverage and outcomes data [56]

Financial Data and Key Metrics Changes - The company reported total revenue of $168.4 million for Q4 2025, an increase of 144% year-over-year [16] - U.S. net product revenue reached $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced its Vision 2040 strategy, aiming for long-term growth and the acquisition of Corstasis Therapeutics to enhance its portfolio [5] - The acquisition of Corstasis is expected to provide global rights to Enbumyst, a first-in-class intranasal diuretic, expanding the company's presence in the cardiometabolic market [11][12] - The company plans to leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to positively impact the company's products [8] - Management emphasized the importance of the upcoming U.S. guidelines and their potential to enhance awareness and prescribing of bempedoic acid [35][44] Other Important Information - The company anticipates completing clinical and regulatory requirements for its triple combination programs by 2027 [8] - The planned acquisition of Corstasis is expected to close in Q2 2026, further strengthening the company's market position [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are prepared for the launch and have sufficient capacity for the product [23] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a comprehensive plan for the medical community [29][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the sentiment from U.S. physicians is positive regarding the European guidelines, which could lead to increased awareness and prescribing [42][44] Question: Triple combination product label expectations - Management indicated that the label for the triple combination will not carry outcomes data but will still be well-received by physicians [49] Question: Collaboration revenue guidance for 2026 - Management highlighted that collaboration revenue will be influenced by ongoing partnerships and the ramp-up of manufacturing [51] Question: Risks of additional concessions in 2026 - Management stated they do not foresee the need for concessions, as they have strong coverage and outcomes data to support their products [56]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [15] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [15] - Collaboration revenue surged to $124.7 million, a 232% increase driven by a one-time payment of $90 million from Otsuka [15] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [14] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [5] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [5] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [8] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [4] - The acquisition is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [6] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [6] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [12] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [12] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for a full-scale launch and will provide updates on the auto-injector after the deal closes [20][24] Question: Updates on ACC guidelines - Management anticipates the guidelines will be released a week before the ACC conference and is preparing a comprehensive plan for outreach [28][30] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and expects similar outcomes from the upcoming U.S. guidelines [40][42] Question: Triple combination product expectations - The triple combination therapy is expected to have high interest, with a focus on both statin intolerant patients and those requiring low-dose statins [60] Question: Corstasis clinical obligations - There are minimal post-market studies required for Enbumyst, which have been accounted for in the updated expense guidance [69] Question: Future sales force expansion - The sales team will expand modestly post-acquisition to ensure coverage of key settings, including heart failure clinics [39]

Q4 and Full Year 2025 Earnings Presentation March 10, 2026 © 2026 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current and planned operational expenses, expected profitability, future operations, commercial products ...

Core Insights - Esperion reported a total revenue growth of 21% year-over-year (Y/Y) to $403.1 million for FY25, with U.S. net product revenue increasing by 38% Y/Y to $159.6 million [1][14] - The company achieved a significant Q4 2025 total revenue growth of 144% Y/Y to $168.4 million, with U.S. net product revenue also growing approximately 38% Y/Y to $43.7 million [1][14] - Esperion announced an agreement to acquire Corstasis Therapeutics, which is expected to enhance its cardiovascular franchise and align with its long-term strategic vision, Vision 2040 [1][4][3] Financial Performance - For Q4 2025, total revenue was $168.4 million, compared to $69.1 million in Q4 2024, marking a 144% increase [14] - Full-year revenue for 2025 reached $403.1 million, up from $332.3 million in 2024, reflecting a 21% increase [14] - U.S. net product sales for Q4 2025 were $43.7 million, up from $31.6 million in Q4 2024, a 38% increase [22] - Collaboration revenue for Q4 2025 was $124.7 million, a 232% increase from $37.6 million in Q4 2024 [22] Market Expansion and Strategic Initiatives - The acquisition of Corstasis Therapeutics is aimed at expanding Esperion's cardiovascular product offerings, particularly with the FDA-approved Enbumyst nasal spray [4][5] - Esperion's U.S. cardiovascular business showed strong momentum, with retail prescription equivalents growing 34% Y/Y and 11.3% quarter-over-quarter [6] - The company is focused on deeper U.S. market penetration and geographic expansion through partnerships, with a goal to enhance its product offerings and market access [3][8] Research and Development - Esperion is advancing its R&D pipeline, including the nomination of ESP-2001 for the treatment of primary sclerosing cholangitis, which represents a potential market opportunity exceeding $1 billion annually [15] - The company plans to develop oral triple combination lipid-lowering tablets, expected to be commercialized in 2027, which could rival existing therapies [10][11] Operational Highlights - Esperion's cash and cash equivalents as of December 31, 2025, totaled $167.9 million, an increase from $144.8 million in 2024 [20] - The company reported a net income of $61.8 million for Q4 2025, compared to a net loss of $21.3 million in Q4 2024 [18][19] - Selling, general, and administrative expenses for Q4 2025 were $41.4 million, a 12% increase from $36.9 million in Q4 2024, primarily due to increased legal costs [22]

Core Insights - Esperion Therapeutics Inc (NASDAQ:ESPR) is recognized as a promising penny stock by analysts, particularly following its strategic agreements to delay generic competition for its drugs NEXLETOL and NEXLIZET until April 19, 2040 [1][2]. Group 1: Strategic Agreements - Esperion has successfully negotiated with Alkem Laboratories to prevent the sale of generic versions of its drugs in the U.S. market until April 2040 [1]. - This agreement is part of a broader strategy to delay generic competition, which also includes a prior deal with Dr. Reddy's Laboratories and other companies [2]. Group 2: Business Strategy and Vision - Esperion has outlined its Vision 2040 plan, aiming to become a leader in cardiometabolic disease therapies by launching at least five products and building a strong pipeline to address unmet medical needs [3]. - The company is also focused on establishing robust international partnerships to enhance its market presence [3]. Group 3: Financial Performance - In 2025, Esperion reported preliminary U.S. net product sales of $156–$160 million, reflecting a significant increase of 35%–38% compared to 2024 [4]. - The company specializes in developing medicines for cardiometabolic diseases and has two drug products approved in over 40 countries [4].

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Acquisition**: Definitive agreement to acquire Corstasis Therapeutics, expanding cardiovascular franchise with Enbumyst, the first FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure [2][3] Key Points Acquisition Details - **Financial Terms**: - Upfront cash payment of $75 million - Royalties on worldwide Enbumyst sales - Up to $180 million in potential milestone payments tied to commercial and regulatory achievements [3] - **Strategic Rationale**: - Strengthens Esperion's cardiovascular portfolio and accelerates revenue growth - Aims to achieve at least 5 marketed products by 2040 through business development and internal pipeline advancement [4][6] Product Overview: Enbumyst - **Approval**: Approved in September 2025 for adults with edema associated with congestive heart failure and other conditions [5] - **Market Potential**: - Addressable outpatient congestive heart failure market valued at over $4 billion - Estimated annual market opportunity of approximately $5 billion based on 2.1 million addressable patients [6][22] - **Unique Selling Proposition**: - First nasal spray diuretic, offering rapid absorption and ease of use compared to oral and IV alternatives - Designed to address unmet needs in outpatient care, potentially reducing hospital readmissions [15][16][24] Market Dynamics - **Congestive Heart Failure (CHF) Statistics**: - Affects nearly 7 million U.S. adults, projected to rise to over 8 million by 2030 - CHF treatment costs estimated at $47 billion in 2020, expected to increase to $142 billion by 2050 [7][8] - CHF contributes to over 452,000 deaths annually in the U.S., accounting for nearly 15% of all deaths [8] - **Patient Journey**: - Patients often experience a cycle of hospital admissions due to fluid overload, with one in four readmitted within 30 days [10][12] Competitive Landscape - **Comparison with Furosemide**: - Enbumyst offers a more convenient delivery method compared to Furosemide's infusion system, which requires patients to remain supine for 5 hours [18][19] - **Market Access Strategy**: - Plans to leverage existing relationships with payers and healthcare providers to maximize access and reimbursement for Enbumyst [64][73] Financial Outlook - **Profitability Goals**: Esperion aims to reach sustainable profitability by 2026, supported by a diversified product portfolio and strong financial position [25] - **Sales Force and Market Penetration**: - Current sales force of approximately 155 representatives, with plans to integrate Corstasis's team to accelerate growth [31][33] Future Developments - **Pipeline Advancements**: - Continued development of next-generation products, including ESP-2001 for primary sclerosing cholangitis and potential offerings in the kidney market [25][26] - **Long-term Vision**: - Esperion's Vision 2040 aims to transform the organization into a global leader in cardiometabolic therapies, addressing significant unmet needs in heart failure and related conditions [27][93] Additional Insights - **Healthcare Economics**: - Emphasis on reducing hospital readmissions and improving patient outcomes as key drivers for payer engagement and market access [66][78] - **Regulatory Environment**: - Anticipation of supportive regulatory frameworks for novel formulations, enhancing market entry opportunities [27] This summary encapsulates the critical aspects of Esperion Therapeutics' strategic update and acquisition of Corstasis Therapeutics, highlighting the potential impact on the cardiovascular market and the company's future direction.

Core Viewpoint - Esperion is focused on executing its current strategies while building for future growth, emphasizing its Vision 2040 initiative [2]. Company Overview - Esperion is currently commercializing two products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid plus ezetimibe) [3]. - The company is in a strong financial position, aiming for sustainable profitability by 2026, supported by durable cash flows and a robust balance sheet [3]. - Esperion has an attractive profit and loss profile, which is bolstered by its partnerships and product pipelines [3].